Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of nalbuphine pretreatment inhibiting sufentanil-induced cough during anesthesia induction
ChiCTR2200057719Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Median effective dose of nalbuphine (ED50) and Cough incidence. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
nalbuphine
Beyond the preview
Go deeper on ChiCTR2200057719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057719.